Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study

Survival was shorter than expected in this unique population-based cohort of advanced digestive HG-NEN, likely due to inclusion of elderly and patients with poor PS. Several novel prognostic factors were identified for NEC and NET G3. An initial sub-effective platinum-based treatment for NET G3 could not be compensated by later-line treatment.

Authors

Institutions

Publication Details

Journal
British Journal of Cancer
Published
2025-05-17
DOI
https://doi.org/10.1038/s41416-025-03054-w
Citations
18
Primary Topic
Neuroendocrine Tumor Research Advances
Type
article
Field-Weighted Citation Impact
24.38

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study

Anna Sundlöv, Elizaveta Mitkina Tabaksblat, Eva Hofsli, Halfdan Sørbye et al.
18 citations
British Journal of Cancer
Neuroendocrine Tumor Research Advances
24.38
article

Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study

Anna Sundlöv, Elizaveta Mitkina Tabaksblat, Eva Hofsli, Halfdan Sørbye, Geir Olav Hjortland, Hege Elvebakken, Jörg Aßmus, Anne Couvelard, Johanna Svensson, Aurel Perren, Eva Tiensuu Janson, Herish Garresori, Christian Kersten, Ulrich Knigge, Morten Ladekarl, Seppo W. Langer, Lene Weber Vestermark, Per Pfeiffer, Inger Marie Bowitz Lothe, Siren Morken
article en
18 citations

Abstract

Survival was shorter than expected in this unique population-based cohort of advanced digestive HG-NEN, likely due to inclusion of elderly and patients with poor PS. Several novel prognostic factors were identified for NEC and NET G3. An initial sub-effective platinum-based treatment for NET G3 could not be compensated by later-line treatment.

British Journal of CancerVol. 133(3)
University of Bern (CH), Uppsala University (SE), University of Copenhagen (DK), Oslo University Hospital (NO), Aalborg University Hospital (DK), Stavanger University Hospital (NO), Haukeland University Hospital (NO), Sahlgrenska University Hospital (SE), Odense University Hospital (DK), Aarhus University Hospital (DK), Rigshospitalet (DK), Hospital of Southern Norway (NO), Ålesund Hospital (NO), St Olav's University Hospital (NO), Skåne University Hospital (SE), Hôpital Bichat-Claude-Bernard (FR), University of Bergen (NO), Aalborg University (DK)
Aarhus Universitet, Aarhus Universitetshospital, Aalborg Universitet, Universitetet i Bergen, Aalborg Universitetshospital, Haukeland Universitetssjukehus, Ipsen, Klinisk Institut, Aalborg Universitet
Openalex Percentile: Top 0%
Neuroendocrine Tumor Research Advances
24.38
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.